Researchers have found a large variety of genetic diagnoses in children with short stature investigated for suspected growth hormone insensitivity.
Researchers find that teenagers with endocrine disorders often have gaps in their knowledge of their condition and how to manage it, making them poorly prepared for transition to adult clinic.
A polygenic risk score for height can predict a child’s adult height with similar accuracy to their mid-parental height, say researchers.
Around 70% of children who survive a brain tumour develop at least one form of endocrine dysfunction, suggests a long-term study of patients attending a hospital in Portugal.
Collagenopathies could account for around one in 10 cases of familial short stature even when there are no obvious signs of dysplasia, say researchers.
A study of children with Noonan syndrome treated in clinical practice shows a good response to growth hormone treatment, with the majority achieving a height within population norms.
A single measurement of plasma levels of a fragment of type X collagen may give an instant picture of how fast a child is growing, say researchers.
Rare copy number variants have been identified in a study of children who have growth hormone insensitivity or insulin-like growth factor-1 insensitivity, shedding light on the genetic basis of their conditions.
Dr Cheri Deal discusses the use of growth hormone in children with Prader-Willi syndrome, the importance of multidisciplinary care and the future of treatment for this genetic condition.
Following the publication of the long-term mortality findings of the SAGhE consortium, we discuss the safety profile of growth hormone with consortium member Stefano Cianfarani.